Exact Mass: 591.3407

Exact Mass Matches: 591.3407

Found 24 metabolites which its exact mass value is equals to given mass value 591.3407, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Alkergot

N-[2-hydroxy-7-(2-methylbutan-2-yl)-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraene-4-carboxamide

C33H45N5O5 (591.3421)


   

veratrine

1,10,11,12,14,23-hexahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-22-yl 2-methylbut-2-enoate

C32H49NO9 (591.3407)


   

veratrine

veratrine

C32H49NO9 (591.3407)


D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents > D014704 - Veratrum Alkaloids D049990 - Membrane Transport Modulators > D062687 - Sodium Channel Agonists

   
   

15-Angeloylgermine

15-Angeloylgermine

C32H49NO9 (591.3407)


   

Angeloylzygadenine beta-N-oxide

Angeloylzygadenine beta-N-oxide

C32H49NO9 (591.3407)


   

Alkergot

Ergoloid-mesylates

C33H45N5O5 (591.3421)


   

Ergoloid_Mesylate

Ergoloid_Mesylate

C33H45N5O5 (591.3421)


   

cevadine

veratrine

C32H49NO9 (591.3407)


D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents > D014704 - Veratrum Alkaloids D049990 - Membrane Transport Modulators > D062687 - Sodium Channel Agonists CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2333

   

LANFK

Leu-Ala-Asn-Phe-Lys

C28H45N7O7 (591.338)


   

Cevadin

veratrine

C32H49NO9 (591.3407)


D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents > D014704 - Veratrum Alkaloids D049990 - Membrane Transport Modulators > D062687 - Sodium Channel Agonists

   

6-Hexadecanoylamido-4-methylumbelliferyl-beta-D-galactopyranoside

6-Hexadecanoylamido-4-methylumbelliferyl-beta-D-galactopyranoside

C32H49NO9 (591.3407)


   

Everolimus Impurity 3

Everolimus Impurity 3

C32H49NO9 (591.3407)


   
   
   

ST 24:3;O4;HexNAc

ST 24:3;O4;HexNAc

C32H49NO9 (591.3407)


   
   

(2s,3s)-2-(dimethylamino)-3-methyl-n-[(3s,4s,7r,11r)-5,8,11-trihydroxy-7-(1h-indol-3-ylmethyl)-3-isopropyl-2-oxa-6,9-diazabicyclo[10.2.2]hexadeca-1(14),5,8,12,15-pentaen-4-yl]pentanimidic acid

(2s,3s)-2-(dimethylamino)-3-methyl-n-[(3s,4s,7r,11r)-5,8,11-trihydroxy-7-(1h-indol-3-ylmethyl)-3-isopropyl-2-oxa-6,9-diazabicyclo[10.2.2]hexadeca-1(14),5,8,12,15-pentaen-4-yl]pentanimidic acid

C33H45N5O5 (591.3421)


   

10,12,14,16,22,23-hexahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-13-yl 2-methylbut-2-enoate

10,12,14,16,22,23-hexahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-13-yl 2-methylbut-2-enoate

C32H49NO9 (591.3407)


   

(2s,3s)-2-(dimethylamino)-3-methyl-n-[(3s,4r,7s,11s)-5,8,11-trihydroxy-7-(1h-indol-3-ylmethyl)-3-isopropyl-2-oxa-6,9-diazabicyclo[10.2.2]hexadeca-1(14),5,8,12,15-pentaen-4-yl]pentanimidic acid

(2s,3s)-2-(dimethylamino)-3-methyl-n-[(3s,4r,7s,11s)-5,8,11-trihydroxy-7-(1h-indol-3-ylmethyl)-3-isopropyl-2-oxa-6,9-diazabicyclo[10.2.2]hexadeca-1(14),5,8,12,15-pentaen-4-yl]pentanimidic acid

C33H45N5O5 (591.3421)


   

(1s,2s,4r,6s,9s,10s,11r,12r,13s,14s,15s,18s,19s,22s,23s,25r)-10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-22-{[(2z)-2-methylbut-2-enoyl]oxy}-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-4-ium-4-olate

(1s,2s,4r,6s,9s,10s,11r,12r,13s,14s,15s,18s,19s,22s,23s,25r)-10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-22-{[(2z)-2-methylbut-2-enoyl]oxy}-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-4-ium-4-olate

C32H49NO9 (591.3407)


   

(1s,2s,6s,9s,10s,11r,12r,13s,14s,15s,16r,18s,19s,22s,23s,25r)-10,12,14,16,22,23-hexahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-13-yl (2z)-2-methylbut-2-enoate

(1s,2s,6s,9s,10s,11r,12r,13s,14s,15s,16r,18s,19s,22s,23s,25r)-10,12,14,16,22,23-hexahydroxy-6,10,19-trimethyl-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-13-yl (2z)-2-methylbut-2-enoate

C32H49NO9 (591.3407)


   

(1s,2s,6s,9s,10s,11r,12r,13s,14s,15s,18s,19s,22s,23s,25r)-10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-22-{[(2z)-2-methylbut-2-enoyl]oxy}-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-4-ium-4-olate

(1s,2s,6s,9s,10s,11r,12r,13s,14s,15s,18s,19s,22s,23s,25r)-10,12,13,14,23-pentahydroxy-6,10,19-trimethyl-22-{[(2z)-2-methylbut-2-enoyl]oxy}-24-oxa-4-azaheptacyclo[12.12.0.0²,¹¹.0⁴,⁹.0¹⁵,²⁵.0¹⁸,²³.0¹⁹,²⁵]hexacosan-4-ium-4-olate

C32H49NO9 (591.3407)


   

2-(dimethylamino)-3-methyl-n-[5,8,11-trihydroxy-7-(1h-indol-3-ylmethyl)-3-isopropyl-2-oxa-6,9-diazabicyclo[10.2.2]hexadeca-1(14),5,8,12,15-pentaen-4-yl]pentanimidic acid

2-(dimethylamino)-3-methyl-n-[5,8,11-trihydroxy-7-(1h-indol-3-ylmethyl)-3-isopropyl-2-oxa-6,9-diazabicyclo[10.2.2]hexadeca-1(14),5,8,12,15-pentaen-4-yl]pentanimidic acid

C33H45N5O5 (591.3421)